Raltegravir + Abacavir-Lamivudine

SHIELD Trial

Raltegravir + Abacavir-Lamivudine
SHIELD: Study Design

Study Design: SHIELD

- **Background**: Open-label, prospective, pilot trial evaluating efficacy of raltegravir in combination with abacavir-lamivudine in treatment-naïve persons with HIV.
- **Inclusion Criteria (n = 37)**
  - Age ≥18 years
  - Antiretroviral therapy naïve
  - HIV RNA >1000 copies/mL
  - HLA-B*5701 negative
  - No resistance to any study drug
- **Treatment Arm**
  - Raltegravir 400 mg BID + Abacavir-Lamivudine QD

→ **Raltegravir 400 mg BID + Abacavir-Lamivudine QD**
(n = 37)

Source: Young B, et al. HIV Clin Trials. 2010;11:260-9.

Raltegravir + Abacavir-Lamivudine
SHIELD: Result

Week 48: Virologic Response (missing/discontinuation = failure)



Source: Young B, et al. HIV Clin Trials. 2010;11:260-9.

National HIV Curriculum

Raltegravir + Abacavir-Lamivudine
SHIELD: Result

Week 48: Changes in Lipid Concentrations



Source: Young B, et al. HIV Clin Trials. 2010;11:260-9.

Raltegravir + Abacavir-Lamivudine
SHIELD: Conclusions

Conclusions: “In this pilot study, abacavir/lamivudine plus raltegravir was effective and generally well-tolerated over 48 weeks with modest changes in fasting lipids.”

Source: Young B, et al. HIV Clin Trials. 2010;11:260-9.

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

National HIV Curriculum

AETC AIDS Education & Training Center Program